Impact of IFN-Free and IFN-Based Treatment on Blood Myeloid Dendritic Cell, Monocyte, Slan-DC, and Activated T Lymphocyte Dynamics During HCV Infection

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2020 Apr 8

PMID 32258171

Citations 1

Authors

Serena Vita

Paola Zuccala

Stefano Savinelli

Claudia Mascia

Raffaella Rossi

Francesco Schiavone

Raffaella Marocco

Tiziana Tieghi

Marco Iannetta

Parni Nijhawan

Maria Antonella Zingaropoli

Gabriella DEttore

Vincenzo Vullo

Claudio Maria Mastroianni

Miriam Lichtner

Affiliations

Soon will be listed here.

Abstract

Chronic hepatitis C virus infection leads to the activation of innate immunity, a key component in HCV fibrosis. In the past, the use of IFN-based treatment regimens did not permit an adequate evaluation of the impact of HCV clearance on immune cells, because of their antiviral and immunomodulatory properties. The recent development of direct-acting antiviral (DAA) therapy, which is associated with high rates of sustained virological response, enables a more accurate analysis of the immunological modifications following HCV eradication. We studied the dynamics of blood myeloid dendritic cells, monocytes, slan-DCs, and T lymphocytes during IFN-free and IFN-based regimens in hepatitis C virus infection.

Citing Articles

Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects.

Zuccala P, Latronico T, Marocco R, Savinelli S, Vita S, Mengoni F Int J Mol Sci. 2022; 23(19).

PMID: 36233234 PMC: 9570033. DOI: 10.3390/ijms231911936.

References

Banchereau J, Steinman R . Dendritic cells and the control of immunity. Nature. 1998; 392(6673):245-52. DOI: 10.1038/32588. View

Mascia C, Vita S, Zuccala P, Marocco R, Tieghi T, Savinelli S . Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon. PLoS One. 2017; 12(6):e0179400. PMC: 5499435. DOI: 10.1371/journal.pone.0179400. View

Gonzalez V, Falconer K, Blom K, Reichard O, Morn B, Lund Laursen A . High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin.... J Virol. 2009; 83(21):11407-11. PMC: 2772767. DOI: 10.1128/JVI.01211-09. View

Liaskou E, Zimmermann H, Li K, Oo Y, Suresh S, Stamataki Z . Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics. Hepatology. 2012; 57(1):385-98. PMC: 4194426. DOI: 10.1002/hep.26016. View

de Baey A, Mende I, Baretton G, Greiner A, Hartl W, Baeuerle P . A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-alpha. J Immunol. 2003; 170(10):5089-94. DOI: 10.4049/jimmunol.170.10.5089. View

Schakel K, Mayer E, Federle C, Schmitz M, Riethmuller G, Rieber E . A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur J Immunol. 1998; 28(12):4084-93. DOI: 10.1002/(SICI)1521-4141(199812)28:12<4084::AID-IMMU4084>3.0.CO;2-4. View

Calleja J, Pascasio J, Ruiz-Antoran B, Gea F, Barcena R, Larrubia J . Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. Liver Int. 2014; 35(1):90-100. DOI: 10.1111/liv.12656. View

Hezode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V . Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014; 147(1):132-142.e4. DOI: 10.1053/j.gastro.2014.03.051. View

Seiwert S, Andrews S, Jiang Y, Serebryany V, Tan H, Kossen K . Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother. 2008; 52(12):4432-41. PMC: 2592891. DOI: 10.1128/AAC.00699-08. View

10.

Negash A, Ramos H, Crochet N, Lau D, Doehle B, Papic N . IL-1β production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog. 2013; 9(4):e1003330. PMC: 3635973. DOI: 10.1371/journal.ppat.1003330. View

11.

Thimme R, Binder M, Bartenschlager R . Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol Rev. 2011; 36(3):663-83. DOI: 10.1111/j.1574-6976.2011.00319.x. View

12.

Sen G . Viruses and interferons. Annu Rev Microbiol. 2001; 55:255-81. DOI: 10.1146/annurev.micro.55.1.255. View

13.

Bourliere M, Oules V, Ansaldi C, Adhoute X, Castellani P . Sofosbuvir as backbone of interferon free treatments. Dig Liver Dis. 2014; 46 Suppl 5:S212-20. DOI: 10.1016/j.dld.2014.09.024. View

14.

Wedemeyer H, He X, Nascimbeni M, Davis A, Greenberg H, Hoofnagle J . Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol. 2002; 169(6):3447-58. DOI: 10.4049/jimmunol.169.6.3447. View

15.

Schakel K, von Kietzell M, Hansel A, Ebling A, Schulze L, Haase M . Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes. Immunity. 2006; 24(6):767-777. DOI: 10.1016/j.immuni.2006.03.020. View

16.

Price J, Murphy R, Shvachko V, Pauly M, Manos M . Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting. Dig Dis Sci. 2014; 59(12):3043-52. PMC: 4237658. DOI: 10.1007/s10620-014-3294-0. View

17.

Imamura M, Ogawa T, Sasaguri Y, Chayama K, Ueno H . Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology. 2005; 128(1):138-46. DOI: 10.1053/j.gastro.2004.10.005. View

18.

Lichtner M, Rossi R, Vita S, Savinelli S, Iannetta M, Mascia C . Blood Myeloid Dendritic Cells and slanDC in Antiretroviral Therapy- Suppressed HIV-Infected Patients. Curr HIV Res. 2016; 14(4):331-9. DOI: 10.2174/1570162x14666160120152100. View

19.

Wilby K, Partovi N, Ford J, Greanya E, Yoshida E . Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol. 2012; 26(4):205-10. PMC: 3354889. DOI: 10.1155/2012/751057. View

20.

Mastroianni C, Lichtner M, Mascia C, Zuccala P, Vullo V . Molecular mechanisms of liver fibrosis in HIV/HCV coinfection. Int J Mol Sci. 2014; 15(6):9184-208. PMC: 4100089. DOI: 10.3390/ijms15069184. View